<p>Arcus Biosciences, Inc.（紐約證券交易所代碼：RCUS - 獲取免費報告）內部人士 Richard Markus 於 12 月 16 日（星期二）出售了 5,052 股該公司的股票。股票的平均售價為 21.88 美元，總價值為 110,537.76 美元。出售後，該內部人士持有 70,141 股公司的股票，價值約為 1,534,685.08 美元。此次交易使其持股減少了 6.72%。該交易已在與證券交易委員會的法律文件中披露，您可以通過此鏈接訪問。</p>
<p>獲取 <strong>Arcus Biosciences</strong> 的提醒：</p>
<ul>
<li>從落後者到領導者：小型股正在崛起</li>
</ul>
<p>Richard Markus 最近還進行了以下交易：</p>
<ul>
<li>在 12 月 17 日（星期三），Richard Markus 出售了 4,494 股 Arcus Biosciences 的股票。這些股票的平均售價為 22.16 美元，總價值為 99,587.04 美元。</li>
</ul>
<h2>Arcus Biosciences 股價下跌 1.2%</h2>
<p>在週四的午盤交易中，紐約證券交易所 RCUS 的股票下跌了 0.26 美元，跌至 22.02 美元。該公司的股票交易量為 1,175,874 股，而其平均交易量為 1,200,446 股。Arcus Biosciences, Inc.的股價一年低點為 6.50 美元，一年高點為 26.40 美元。該公司的 50 日簡單移動平均線為 20.82 美元，200 日簡單移動平均線為 13.98 美元。該公司的債務與股本比率為 0.22，流動比率為 3.65，速動比率為 3.65。該股票的市值為 23.8 億美元，市盈率為-6.40，貝塔值為 0.75。</p>
<ul>
<li>MarketBeat 週報 – 7/10 - 7/14</li>
</ul>
<p>Arcus Biosciences（紐約證券交易所代碼：RCUS - 獲取免費報告）最近在 10 月 28 日（星期二）發佈了其財報。該公司報告本季度每股收益（EPS）為-1.27 美元，超出市場共識預期的-1.33 美元 0.06 美元。該公司本季度的收入為 2600 萬美元，而分析師預期為 1989 萬美元。Arcus Biosciences 的淨利潤率為-136.40%，股本回報率為-68.17%。與去年同期相比，該公司的季度收入下降了 45.8%。在去年同期，該公司每股收益為-1.00 美元。平均而言，賣方分析師預計 Arcus Biosciences, Inc.在當前財年將發佈-3.15 的每股收益。</p>
<h2>機構資金流入和流出</h2>
<p>幾家機構投資者最近調整了對 RCUS 的持股。Amalgamated Bank 在第三季度將其在 Arcus Biosciences 的持股增加了 3.9%。Amalgamated Bank 目前持有 19,533 股該公司的股票，價值 266,000 美元，此前在上個季度又購買了 736 股。Creative Planning 在第三季度將其在 Arcus Biosciences 的持股增加了 2.7%。Creative Planning 目前持有 29,629 股該公司的股票，價值 403,000 美元，此前在上個季度又購買了 771 股。GAMMA Investing LLC 在第三季度將其在 Arcus Biosciences 的持股增加了 59.1%。GAMMA Investing LLC 目前持有 2,748 股該公司的股票，價值 37,000 美元，此前在此期間又收購了 1,021 股。賓夕法尼亞州公共學校僱員退休系統在第二季度將其在 Arcus Biosciences 的持股增加了 8.0%。賓夕法尼亞州公共學校僱員退休系統目前持有 17,398 股該公司的股票，價值 142,000 美元，此前在上個季度又收購了 1,294 股。最後，Parallel Advisors LLC 在第二季度將其在 Arcus Biosciences 的持股增加了 1.6%。Parallel Advisors LLC 目前持有 88,007 股該公司的股票，價值 716,000 美元，此前在此期間又收購了 1,422 股。92.89% 的股票目前由機構投資者和對沖基金持有。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>Gilead 通過在 AlloVir 和 Arcus 的投資擴大生物科技足跡</li>
</ul>
<p>幾家券商最近對 RCUS 發佈了報告。Weiss Ratings 在 10 月 8 日（星期三）的研究報告中重新發布了對 Arcus Biosciences 股票的 “賣出（d-）” 評級。Wall Street Zen 在週日將 Arcus Biosciences 的評級從 “賣出” 上調至 “持有”。Wedbush 在 10 月 29 日（星期三）的研究報告中對 Arcus Biosciences 設定了 35.00 美元的目標價，並給予該股票 “跑贏大盤” 的評級。瑞銀集團在週一的研究報告中重新發布了對 Arcus Biosciences 股票的 “買入” 評級。最後，花旗集團在 12 月 12 日（星期五）的研究報告中重申了對 Arcus Biosciences 股票的 “買入” 評級。八位投資分析師對該股票給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat，該股票目前的共識評級為 “適度買入”，共識目標價為 28.89 美元。</p>
<p><strong>獲取我們最新的 RCUS 研究報告</strong></p>
<h2>Arcus Biosciences 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Arcus Biosciences, Inc.是一家臨牀階段的生物製藥公司，專注於在美國開發和商業化癌症療法。該公司的管線產品包括 Domvanalimab，一種抗 TIGIT 抗體，目前處於第二階段和第三階段臨牀試驗；以及 AB308，一種正在研究的抗 TIGIT 單克隆抗體，目前處於第一階段 b 臨牀試驗，旨在研究晚期實體瘤和血液惡性腫瘤患者。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票超過 Arcus Biosciences</li>
<li>賣空 - 利與弊</li>
<li>博通股票暴跌 20%——但華爾街認為其將飆升至 500 美元</li>
<li>如何在 7 個步驟中投資大麻股票</li>
<li>忘掉芯片：AI 反彈的 4 個工業投資機會</li>
<li>TSX 風險投資交易所（前身為加拿大風險投資交易所）</li>
<li>MongoDB 可能創下新高——但您需要迅速行動</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJDVVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJDVVM"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Arcus Biosciences 嗎？</h2>
<p>在你考慮 Arcus Biosciences 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Arcus Biosciences 並不在名單上。</p>
<p>雖然 Arcus Biosciences 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

RCUS

<p>Richard Markus，Arcus Biosciences 的內部人士，以每股 21.88 美元的價格出售了 5,052 股公司股票，總計 110,537.76 美元。這筆交易使他的持股減少了 6.72%，剩餘 70,141 股，價值 1,534,685.08 美元。該交易已在向美國證券交易委員會（SEC）的法律文件中披露。此外，Markus 在第二天以每股 22.16 美元的價格出售了 4,494 股。Arcus Biosciences 的股票目前交易價格為 22.02 美元，市值為 23.8 億美元</p>

<p>Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) insider Richard Markus sold 5,052 shares of the business's stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $21.88, for a total value of $110,537.76. Following the sale, the insider owned 70,141 shares of the company's stock, valued at approximately $1,534,685.08. The trade was a 6.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this link.</p>
<div class="lb-trans"><p>Arcus Biosciences, Inc.（紐約證券交易所代碼：RCUS - 獲取免費報告）內部人士 Richard Markus 於 12 月 16 日（星期二）出售了 5,052 股該公司的股票。股票的平均售價為 21.88 美元，總價值為 110,537.76 美元。出售後，該內部人士持有 70,141 股公司的股票，價值約為 1,534,685.08 美元。此次交易使其持股減少了 6.72%。該交易已在與證券交易委員會的法律文件中披露，您可以通過此鏈接訪問。</p>
</div><p>Get <strong>Arcus Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Arcus Biosciences</strong> 的提醒：</p>
</div><ul>
<li>From laggards to leaders: Small caps on the rise</li>
</ul>
<div class="lb-trans"><ul>
<li>從落後者到領導者：小型股正在崛起</li>
</ul>
</div><p>Richard Markus also recently made the following trade(s):</p>
<div class="lb-trans"><p>Richard Markus 最近還進行了以下交易：</p>
</div><ul>
<li>On Wednesday, December 17th, Richard Markus sold 4,494 shares of Arcus Biosciences stock. The shares were sold at an average price of $22.16, for a total value of $99,587.04.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 12 月 17 日（星期三），Richard Markus 出售了 4,494 股 Arcus Biosciences 的股票。這些股票的平均售價為 22.16 美元，總價值為 99,587.04 美元。</li>
</ul>
</div><h2>Arcus Biosciences Trading Down 1.2%</h2>
<div class="lb-trans"><h2>Arcus Biosciences 股價下跌 1.2%</h2>
</div><p>Shares of NYSE RCUS traded down $0.26 during mid-day trading on Thursday, hitting $22.02. The company's stock had a trading volume of 1,175,874 shares, compared to its average volume of 1,200,446. Arcus Biosciences, Inc. has a one year low of $6.50 and a one year high of $26.40. The company's fifty day simple moving average is $20.82 and its 200-day simple moving average is $13.98. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.65 and a quick ratio of 3.65. The stock has a market cap of $2.38 billion, a price-to-earnings ratio of -6.40 and a beta of 0.75.</p>
<div class="lb-trans"><p>在週四的午盤交易中，紐約證券交易所 RCUS 的股票下跌了 0.26 美元，跌至 22.02 美元。該公司的股票交易量為 1,175,874 股，而其平均交易量為 1,200,446 股。Arcus Biosciences, Inc.的股價一年低點為 6.50 美元，一年高點為 26.40 美元。該公司的 50 日簡單移動平均線為 20.82 美元，200 日簡單移動平均線為 13.98 美元。該公司的債務與股本比率為 0.22，流動比率為 3.65，速動比率為 3.65。該股票的市值為 23.8 億美元，市盈率為-6.40，貝塔值為 0.75。</p>
</div><ul>
<li>MarketBeat Week in Review – 7/10 - 7/14</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週報 – 7/10 - 7/14</li>
</ul>
</div><p>Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its earnings results on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, beating the consensus estimate of ($1.33) by $0.06. The company had revenue of $26.00 million during the quarter, compared to analysts' expectations of $19.89 million. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The business's revenue for the quarter was down 45.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.00) EPS. On average, sell-side analysts anticipate that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Arcus Biosciences（紐約證券交易所代碼：RCUS - 獲取免費報告）最近在 10 月 28 日（星期二）發佈了其財報。該公司報告本季度每股收益（EPS）為-1.27 美元，超出市場共識預期的-1.33 美元 0.06 美元。該公司本季度的收入為 2600 萬美元，而分析師預期為 1989 萬美元。Arcus Biosciences 的淨利潤率為-136.40%，股本回報率為-68.17%。與去年同期相比，該公司的季度收入下降了 45.8%。在去年同期，該公司每股收益為-1.00 美元。平均而言，賣方分析師預計 Arcus Biosciences, Inc.在當前財年將發佈-3.15 的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Several institutional investors have recently modified their holdings of RCUS. Amalgamated Bank increased its position in Arcus Biosciences by 3.9% during the third quarter. Amalgamated Bank now owns 19,533 shares of the company's stock worth $266,000 after buying an additional 736 shares during the last quarter. Creative Planning lifted its position in shares of Arcus Biosciences by 2.7% in the third quarter. Creative Planning now owns 29,629 shares of the company's stock valued at $403,000 after buying an additional 771 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Arcus Biosciences by 59.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company's stock worth $37,000 after acquiring an additional 1,021 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in shares of Arcus Biosciences by 8.0% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,398 shares of the company's stock worth $142,000 after acquiring an additional 1,294 shares during the last quarter. Finally, Parallel Advisors LLC raised its stake in Arcus Biosciences by 1.6% in the 2nd quarter. Parallel Advisors LLC now owns 88,007 shares of the company's stock valued at $716,000 after acquiring an additional 1,422 shares during the period. 92.89% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>幾家機構投資者最近調整了對 RCUS 的持股。Amalgamated Bank 在第三季度將其在 Arcus Biosciences 的持股增加了 3.9%。Amalgamated Bank 目前持有 19,533 股該公司的股票，價值 266,000 美元，此前在上個季度又購買了 736 股。Creative Planning 在第三季度將其在 Arcus Biosciences 的持股增加了 2.7%。Creative Planning 目前持有 29,629 股該公司的股票，價值 403,000 美元，此前在上個季度又購買了 771 股。GAMMA Investing LLC 在第三季度將其在 Arcus Biosciences 的持股增加了 59.1%。GAMMA Investing LLC 目前持有 2,748 股該公司的股票，價值 37,000 美元，此前在此期間又收購了 1,021 股。賓夕法尼亞州公共學校僱員退休系統在第二季度將其在 Arcus Biosciences 的持股增加了 8.0%。賓夕法尼亞州公共學校僱員退休系統目前持有 17,398 股該公司的股票，價值 142,000 美元，此前在上個季度又收購了 1,294 股。最後，Parallel Advisors LLC 在第二季度將其在 Arcus Biosciences 的持股增加了 1.6%。Parallel Advisors LLC 目前持有 88,007 股該公司的股票，價值 716,000 美元，此前在此期間又收購了 1,422 股。92.89% 的股票目前由機構投資者和對沖基金持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus</li>
</ul>
<div class="lb-trans"><ul>
<li>Gilead 通過在 AlloVir 和 Arcus 的投資擴大生物科技足跡</li>
</ul>
</div><p>Several brokerages have recently issued reports on RCUS. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Arcus Biosciences in a research report on Wednesday, October 8th. Wall Street Zen upgraded Arcus Biosciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Sunday. Wedbush set a $35.00 price objective on Arcus Biosciences and gave the stock an &#34;outperform&#34; rating in a research report on Wednesday, October 29th. UBS Group reissued a &#34;buy&#34; rating on shares of Arcus Biosciences in a research report on Monday. Finally, Citigroup reaffirmed a &#34;buy&#34; rating on shares of Arcus Biosciences in a research report on Friday, December 12th. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $28.89.</p>
<div class="lb-trans"><p>幾家券商最近對 RCUS 發佈了報告。Weiss Ratings 在 10 月 8 日（星期三）的研究報告中重新發布了對 Arcus Biosciences 股票的 “賣出（d-）” 評級。Wall Street Zen 在週日將 Arcus Biosciences 的評級從 “賣出” 上調至 “持有”。Wedbush 在 10 月 29 日（星期三）的研究報告中對 Arcus Biosciences 設定了 35.00 美元的目標價，並給予該股票 “跑贏大盤” 的評級。瑞銀集團在週一的研究報告中重新發布了對 Arcus Biosciences 股票的 “買入” 評級。最後，花旗集團在 12 月 12 日（星期五）的研究報告中重申了對 Arcus Biosciences 股票的 “買入” 評級。八位投資分析師對該股票給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat，該股票目前的共識評級為 “適度買入”，共識目標價為 28.89 美元。</p>
</div><p><strong>Get Our Latest Research Report on RCUS</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 RCUS 研究報告</strong></p>
</div><h2>Arcus Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Arcus Biosciences 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.</p>
<div class="lb-trans"><p>Arcus Biosciences, Inc.是一家臨牀階段的生物製藥公司，專注於在美國開發和商業化癌症療法。該公司的管線產品包括 Domvanalimab，一種抗 TIGIT 抗體，目前處於第二階段和第三階段臨牀試驗；以及 AB308，一種正在研究的抗 TIGIT 單克隆抗體，目前處於第一階段 b 臨牀試驗，旨在研究晚期實體瘤和血液惡性腫瘤患者。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Arcus Biosciences</li>
<li>Short Selling - The Pros and Cons</li>
<li>Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500</li>
<li>How to invest in marijuana stocks in 7 steps</li>
<li>Forget the Chips: 4 Industrial Plays for the AI Rebound</li>
<li>TSX Venture Exchange (Formerly Canadian Venture Exchange)</li>
<li>MongoDB Could Hit Record Highs—But You’ll Need to Move Fast</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Arcus Biosciences</li>
<li>賣空 - 利與弊</li>
<li>博通股票暴跌 20%——但華爾街認為其將飆升至 500 美元</li>
<li>如何在 7 個步驟中投資大麻股票</li>
<li>忘掉芯片：AI 反彈的 4 個工業投資機會</li>
<li>TSX 風險投資交易所（前身為加拿大風險投資交易所）</li>
<li>MongoDB 可能創下新高——但您需要迅速行動</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJDVVM" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NYSE&amp;Symbol=RCUS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Arcus Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Arcus Biosciences 嗎？</h2>
</div><p>Before you consider Arcus Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Arcus Biosciences 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Arcus Biosciences 並不在名單上。</p>
</div><p>While Arcus Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Arcus Biosciences 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

理查德·馬庫斯出售了 5,052 股 Arcus Biosciences（紐約證券交易所代碼：RCUS）的股票